Abstract: A mounting apparatus for a battery module includes a base, a latching member slidably attached to the base to fix the battery module, and an operating member rotatably attached to the base. When the operating member of the mounting apparatus is rotated, the latching member is driven to slide to disengage from the battery module.

Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: A cover positioning structure of a dual-usage portable computer is disclosed, which comprises a base, at least one slide block sliding on the base, at least one elastic slice imposing a pressure to the at least one slide block, and a rotary member rotated relative to the base. When rotated, a positioning protrusion of the rotary member is correspondingly positioned to a positioning recess of the at least one slide block. Therefore, the structure aforesaid not only achieves the positioning purpose of being damage-free, but also is cost-effective in having a minimum of elements and manufacture processes.

Abstract: A transdermal drug delivery system includes a drug source, an adhesive for applying the system to a skin surface, a penetration enhancer for enhancing penetration of the drug into the skin surface, an energy source and a contact for conveying energy from said energy source through said adhesive and the penetrating enhancer.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: Lacrimal canalicular inserts include a polymeric component and a therapeutic component. The therapeutic component is released from the inserts for extended periods of time, such as for more than about 2 weeks after placement in a lacrimal canaliculus of an individual. The polymeric component may include one or more non-biodegradable polymers, one or more biodegradable polymers, or combinations thereof. The therapeutic component may include one or more therapeutic agents. Therapeutically effective amounts of the therapeutic component are released from the insert and provide sustained drug delivery to the eye and/or the nasolacrimal system of the individual.

Abstract: A swimming training apparatus automatically adjusts a user's position at the water surface of a swimming pool according to the user's swimming conditions by a resilient component installed in a position adjusting device. The swimming training apparatus includes an arc support structure, a position adjusting device and a connecting element. When the user swims away from the swimming training apparatus, the pulling force produced by the swimming winds the drive gear to store resilience to the resilient component. The gear set drives two rollers to move the position adjusting device towards a pool side. When the user stops swimming, the resilient component releases the resilience so that the drive gear shortens the connecting element and moves the position adjusting device towards the original position. The invention enables users to swim at different distances within a safe range or flow safely on the water surface of the swimming pool.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Abstract: Prednisolone acetate compositions, and methods, eye drops, and medicaments related thereto, are disclosed herein.

Abstract: Dosage forms comprising therapeutically active compounds are disclosed herein.

Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Abstract: A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH (1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

Abstract: A common lock used in a dual-usage portable computer formed of a base member and a display is disclosed to include a left-side hook and a right-side hook respectively pivoted to the base member on the inside, and an elongated operating frame bar axially slidably mounted inside the base member of the portable computer and coupled between the left-side hook and the right-side hook for operation by the user to bias the left-side hook and the right-side hook by means of a lever action and to further force the left-side hook and the right-side hook out of a respective through hole at the base member into engagement with a respective retaining block at the display to lock the display to the base member.

Abstract: A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets of Memantine tablets are provided with each tablet in set having a common dose of medication and a different dose than a tablet of a different set. Each set of tablets is disposed in receivers of one having an adjacent row and an adjacent column. Indicia is provided and disposed adjacent to the columns and rows for displaying common days and successive weeks.